Related Experiment Video
Updated: May 29, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Cell therapeutics in Parkinson's disease
Olle Lindvall1, Anders Björklund
1Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, University Hospital, SE-22184 Lund, Sweden. Olle.Lindvall@med.lu.se
Summary
Parkinson's disease (PD) cell therapy aims to replace lost dopamine (DA) neurons. Research explores fetal tissue and stem cells, addressing graft survival and side effects for future treatments.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Therapy
Background:
- Parkinson's disease (PD) is characterized by the degeneration of nigrostriatal dopamine (DA) neurons.
- Intrastriatal transplantation of immature DA neurons shows promise for functional restoration in PD animal models.
Purpose of the Study:
- To review the clinical translation of DA neuron replacement strategies for Parkinson's disease.
- To discuss advancements, challenges, and future directions in cell therapy for PD.
Main Methods:
- Summary of lessons learned from early clinical trials using human fetal mesencephalic tissue grafts.
- Analysis of recent findings on graft susceptibility and graft-induced dyskinesias.
- Review of stem cell-derived and patient-specific DA neuron generation for clinical use.
Main Results:
- Early trials provided insights but highlighted long-term graft susceptibility and graft-induced dyskinesias as adverse events.
- Generation of DA neurons from stem cells and patient-specific cells is advancing, with specific clinical requirements identified.
- A new clinical trial using fetal mesencephalic tissue transplantation is being initiated.
Conclusions:
- Cell therapy for Parkinson's disease requires further scientific and clinical advancements for competitive efficacy.
- Addressing graft survival, disease susceptibility, and adverse events like dyskinesias is crucial for successful PD cell therapy.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...